Τετάρτη, 20 Μαρτίου 2019

Clinical Trials

Pfizer gets FDA approval for oncology biosimilar Trazimera
Trazimera has been approved to treat human epidermal growth factor receptor-2 (HER2) overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Pfizer Oncology global president The post Pfizer gets FDA approval for oncology biosimilar Trazimera appeared first on Pharmaceutical Business review.
PBR - Clinical Trials News
Tue Mar 12, 2019 10:56
Clinical stage biotech company InventisBio closes $70m Series C financing
This round of investment was co-led by Advantech Capital and CMBI, followed by Pudong Innotek. Also participating were existing investors Lilly Asia Venture (LAV) and OrbiMed Asia. "The The post Clinical stage biotech company InventisBio closes $70m Series C financing appeared first on Pharmaceutical Business review.
PBR - Clinical Trials News
Tue Mar 12, 2019 08:52
Nallian to launch global pharma tracker for temperature-controlled shipments
Providing unparalleled levels of transparency and visibility, it empowers pharma actors to efficiently detect, act upon and ultimately prevent costly temperature excursions – currently causing billions worth of The post Nallian to launch global pharma tracker for temperature-controlled shipments appeared first on Pharmaceutical Business review.
PBR - Clinical Trials News
Mon Mar 11, 2019 12:25
Roche gets EC nod for Tecentriq and Avastin combo for first-line lung cancer
The EC has approved Tecentriq in combination with Avastin, paclitaxel and carboplatin, for the first-line treatment of adults with metastatic non-squamous non-small cell lung cancer (NSCLC). Tecentriq, in The post Roche gets EC nod for Tecentriq and Avastin combo for first-line lung cancer appeared first on Pharmaceutical Business review.
PBR - Clinical Trials News
Mon Mar 11, 2019 10:21
TaiwanJ Pharmaceuticals out-licenses liver drug candidate in Asia
On March 2nd, 2019, TaiwanJ announced that its JKB-122, an effective phase 2 nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) drug candidate, had been successfully licensed out to The post TaiwanJ Pharmaceuticals out-licenses liver drug candidate in Asia appeared first on Pharmaceutical Business review.
PBR - Clinical Trials News
Mon Mar 11, 2019 10:21
Gilead announces data from two studies supporting further development of investigational HIV-1 capsid inhibitor GS-6207
Interim blinded data from a Phase 1 study in healthy trial participants demonstrated that single doses of GS-6207 of up to 450 mg, administered subcutaneously, achieved sustained concentration The post Gilead announces data from two studies supporting further development of investigational HIV-1 capsid inhibitor GS-6207 appeared first on Pharmaceutical Business review.
PBR - Clinical Trials News
Fri Mar 08, 2019 13:37
GTx, Oncternal Therapeutics sign merger deal to create new clinical-stage oncology firm
Oncternal Therapeutics will be the name of the combined company, which will engage in the development of potential first-in-class therapeutic candidates for cancers. As per terms of the The post GTx, Oncternal Therapeutics sign merger deal to create new clinical-stage oncology firm appeared first on Pharmaceutical Business review.
PBR - Clinical Trials News
Fri Mar 08, 2019 11:37
ViiV Healthcare reports positive data for two phase 3 HIV trials of cabotegravir, rilpivirine regimen
These two studies met their primary endpoints, showing that the combination of ViiV Healthcare's cabotegravir and Janssen's rilpivirine, injected every four weeks, was non-inferior in maintaining viral suppression The post ViiV Healthcare reports positive data for two phase 3 HIV trials of cabotegravir, rilpivirine regimen appeared first on Pharmaceutical Business review.
PBR - Clinical Trials News
Fri Mar 08, 2019 09:36
UK's NICE seeks additional data on blood cancer drug Blincyto
The committee concluded that Blincyto holds capacity to offer significant clinical benefits, while addition data on cost-effectiveness is required to evaluate its credibility for NHS funding. NICE has The post UK's NICE seeks additional data on blood cancer drug Blincyto appeared first on Pharmaceutical Business review.
PBR - Clinical Trials News
Thu Mar 07, 2019 11:28
Beam Therapeutics secures $135m funds to expand pipeline of precision genetic medicines
Proceeds from the financing will be used to advance the company's development of next-generation CRISPR technologies, expand its pipeline of base editing programs, and further extend its scientific The post Beam Therapeutics secures $135m funds to expand pipeline of precision genetic medicines appeared first on Pharmaceutical Business review.
PBR - Clinical Trials News
Thu Mar 07, 2019 11:28
Novo Nordisk's Ozempic meets primary endpoint in Sustain 9 diabetes trial
The 30-week long trial, dubbed Sustain 9, assessed the efficacy and safety of Ozempic injection 1.0 mg in combination with the SGLT-2 inhibitors against placebo. The drug was The post Novo Nordisk's Ozempic meets primary endpoint in Sustain 9 diabetes trial appeared first on Pharmaceutical Business review.
PBR - Clinical Trials News
Thu Mar 07, 2019 11:28
HIV remission achieved in second patient
The case report, published in Nature and carried out with partners at the University of Cambridge and the University of Oxford, comes ten years after the first such The post HIV remission achieved in second patient appeared first on Pharmaceutical Business review.
PBR - Clinical Trials News
Thu Mar 07, 2019 11:28
Ligand sells Promacta assets and Royalty for $827m
Promacta (eltrombopag) is known as Revolade outside the US and is marketed worldwide by Novartis. This transaction is expected to close on Wednesday, March 6, 2019. "After extensive The post Ligand sells Promacta assets and Royalty for $827m appeared first on Pharmaceutical Business review.
PBR - Clinical Trials News
Wed Mar 06, 2019 11:23
FDA approves Janssen's Spravato CIII nasal spray to treat depression
The approval has been granted for Spravato for use in conjunction with an oral antidepressant in adults with TRD, who have cycled through multiple treatments without relief. Janssen The post FDA approves Janssen's Spravato CIII nasal spray to treat depression appeared first on Pharmaceutical Business review.
PBR - Clinical Trials News
Wed Mar 06, 2019 11:23
Verona's ensifentrine DPI formulation succeeds in part 1 of COPD trial
Also known as RPL554, ensifentrine, is being investigated as an inhaled dual inhibitor of the phosphodiesterase 3 and 4 enzymes and is designed to have bronchodilator and anti-inflammatory The post Verona's ensifentrine DPI formulation succeeds in part 1 of COPD trial appeared first on Pharmaceutical Business review.
PBR - Clinical Trials News
Wed Mar 06, 2019 11:23

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Δημοφιλείς αναρτήσεις